{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T10:29:04Z","timestamp":1782210544574,"version":"3.54.5"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinicalnutritionjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Nutrition"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.clnu.2025.03.024","type":"journal-article","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T21:42:27Z","timestamp":1743889347000},"page":"52-56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Overcoming barriers to unlock the therapeutic potential of saroglitazar for the management of metabolic dysfunction-associated steatotic liver disease"],"prefix":"10.1016","volume":"49","author":[{"given":"Murali Krishna","family":"Moka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepalaxmi","family":"Rathakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.K.","family":"Sriram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7101-8513","authenticated-orcid":false,"given":"Melvin","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clnu.2025.03.024_bib1","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","article-title":"Epidemiology of metabolic dysfunction-associated steatotic liver disease","volume":"31","author":"Younossi","year":"2025","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.clnu.2025.03.024_bib2","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2147\/CEOR.S472446","article-title":"Economic impact of metabolic dysfunction-Associated Steatotic Liver Disease (MASLD) in Italy. Analysis and perspectives","volume":"16","author":"Torre","year":"2024","journal-title":"Clin Outcomes Res"},{"key":"10.1016\/j.clnu.2025.03.024_bib3","doi-asserted-by":"crossref","first-page":"ITC1","DOI":"10.7326\/ANNALS-24-02933","article-title":"Metabolic dysfunction\u2013associated steatotic liver disease","volume":"178","author":"Ali","year":"2025","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clnu.2025.03.024_bib4","doi-asserted-by":"crossref","first-page":"197","DOI":"10.7570\/jomes23052","article-title":"Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): a State-of-the-Art review","volume":"32","author":"Chan","year":"2023","journal-title":"J Obes Metab Syndr"},{"key":"10.1016\/j.clnu.2025.03.024_bib5","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.54707","article-title":"Estimated burden of metabolic dysfunction\u2013associated steatotic liver disease in US adults, 2020 to 2050","volume":"8","author":"Le","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clnu.2025.03.024_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.155912","article-title":"Deciphering the molecular pathways of saroglitazar: a dual PPAR \u03b1\/\u03b3 agonist for managing metabolic NAFLD","volume":"155","author":"Ezhilarasan","year":"2024","journal-title":"Metabolism"},{"key":"10.1016\/j.clnu.2025.03.024_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0269531","article-title":"Efficacy and safety of saroglitazar for the management of dyslipidemia: a systematic review and meta-analysis of interventional studies","volume":"17","author":"Chhabra","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.clnu.2025.03.024_bib8","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/liv.13634","article-title":"Dual <scp>PPAR<\/scp> \u03b1\/\u03b3 agonist saroglitazar improves liver histopathology and biochemistry in experimental <scp>NASH<\/scp> models","volume":"38","author":"Jain","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.clnu.2025.03.024_bib9","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1177\/1932296813518680","article-title":"A multicenter, prospective, randomized, Double-blind study to evaluate the safety and efficacy of saroglitazar 2 and 4 mg compared to Pioglitazone 45 mg in Diabetic Dyslipidemia (PRESS V)","volume":"8","author":"Pai","year":"2014","journal-title":"J Diabetes Sci Technol"},{"key":"10.1016\/j.clnu.2025.03.024_bib10","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12933-020-01073-w","article-title":"Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study)","volume":"19","author":"Krishnappa","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.clnu.2025.03.024_bib11","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1016\/j.cgh.2020.10.051","article-title":"A phase 2 double blinded, randomized controlled trial of saroglitazar in patients with nonalcoholic steatohepatitis","volume":"19","author":"Siddiqui","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.clnu.2025.03.024_bib12","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1016\/j.cgh.2023.01.018","article-title":"Saroglitazar, a dual PPAR \u03b1\/\u03b3 agonist, improves atherogenic dyslipidemia in patients with non-cirrhotic nonalcoholic fatty liver disease: a pooled analysis","volume":"21","author":"Siddiqui","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.clnu.2025.03.024_bib13","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jceh.2021.03.012","article-title":"Safety and efficacy of saroglitazar in nonalcoholic fatty liver patients with diabetic dyslipidemia\u2014A prospective, interventional, pilot study","volume":"12","author":"Rajesh","year":"2022","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.clnu.2025.03.024_bib14","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12933-019-0884-3","article-title":"New dual peroxisome proliferator activated receptor agonist\u2014Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence","volume":"18","author":"Kaul","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.clnu.2025.03.024_bib15","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s40360-021-00524-8","article-title":"Saroglitazar improved hepatic steatosis and fibrosis by modulating inflammatory cytokines and adiponectin in an animal model of non-alcoholic steatohepatitis","volume":"22","author":"Akbari","year":"2021","journal-title":"BMC Pharmacol Toxicol"},{"key":"10.1016\/j.clnu.2025.03.024_bib16","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/hep.31843","article-title":"Saroglitazar, a PPAR-\u03b1\/\u03b3 agonist, for treatment of NAFLD: a randomized controlled double-blind phase 2 trial","volume":"74","author":"Gawrieh","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.clnu.2025.03.024_bib17","doi-asserted-by":"crossref","DOI":"10.14309\/01.ajg.0000955360.84068.3c","article-title":"S1430 saroglitazar improves metabolic profile, hepatic steatosis, inflammation, and fibrosis in patients with non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: a systematic review","volume":"118","author":"Duseja","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clnu.2025.03.024_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.31579\/2641-8975\/003","article-title":"Real time clinical safety and effectiveness of long term use of saroglitazar in Indian patients with diabetic dyslipidemia having abnormal metabolic parameters","volume":"1","author":"Chatterjee","year":"2018","journal-title":"Diabetes Islet Biol"},{"key":"10.1016\/j.clnu.2025.03.024_bib19","doi-asserted-by":"crossref","first-page":"7706","DOI":"10.1038\/srep07706","article-title":"Observational study of effects of saroglitazar on glycaemic and lipid parameters on Indian patients with type 2 diabetes","volume":"5","author":"Chatterjee","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.clnu.2025.03.024_bib20","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1097\/LVT.0000000000000110","article-title":"Saroglitazar improves nonalcoholic fatty liver disease and metabolic health in liver transplant recipients","volume":"29","author":"Siddiqui","year":"2023","journal-title":"Liver Transplant"},{"key":"10.1016\/j.clnu.2025.03.024_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.jceh.2024.101449","article-title":"Emerging combination of saroglitazar and vitamin E for the treatment of NAFLD and NASH","volume":"14","author":"Tavaglione","year":"2024","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.clnu.2025.03.024_bib22","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000327","article-title":"A multicenter, open-label, single-arm study to evaluate the efficacy and safety of saroglitazar in patients with primary biliary cholangitis","volume":"12","author":"Vuppalanchi","year":"2021","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.clnu.2025.03.024_bib23","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.36922\/itps.3560","article-title":"The role of saroglitazar in the treatment of metabolic dysfunction-associated steatohepatitis in non-diabetic patients: a prospective observational study","volume":"7","author":"Kumar","year":"2024","journal-title":"INNOSC Theranostics Pharmacol Sci"},{"key":"10.1016\/j.clnu.2025.03.024_bib24","doi-asserted-by":"crossref","first-page":"11","DOI":"10.9734\/ajmah\/2024\/v22i91085","article-title":"Clinical case series on assessment of therapeutic efficacy of saroglitazar in MASLD patients","volume":"22","author":"Dang","year":"2024","journal-title":"Asian J Med Heal"},{"key":"10.1016\/j.clnu.2025.03.024_bib25","series-title":"P15 comparative efficacy of pioglitazone and saroglitazar in non-alcoholic fatty liver disease: a Bayesian network meta-analysis. Poster present","first-page":"A22","author":"Ghosal","year":"2023"},{"key":"10.1016\/j.clnu.2025.03.024_bib26","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3390\/biomedicines13010135","article-title":"Integrated management of cardiovascular\u2013renal\u2013hepatic\u2013metabolic syndrome: expanding roles of SGLT2is, GLP-1RAs, and GIP\/GLP-1RAs","volume":"13","author":"Theodorakis","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.clnu.2025.03.024_bib27","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1186\/s12933-024-02500-y","article-title":"Updated evidence on cardiovascular and renal effects of GLP-1 receptor agonists and combination therapy with SGLT2 inhibitors and finerenone: a narrative review and perspectives","volume":"23","author":"Sawami","year":"2024","journal-title":"Cardiovasc Diabetol"}],"container-title":["Clinical Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0261561425000925?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0261561425000925?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T14:14:03Z","timestamp":1747318443000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0261561425000925"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":27,"alternative-id":["S0261561425000925"],"URL":"https:\/\/doi.org\/10.1016\/j.clnu.2025.03.024","relation":{},"ISSN":["0261-5614"],"issn-type":[{"value":"0261-5614","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overcoming barriers to unlock the therapeutic potential of saroglitazar for the management of metabolic dysfunction-associated steatotic liver disease","name":"articletitle","label":"Article Title"},{"value":"Clinical Nutrition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clnu.2025.03.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}